磷霉素氨丁三醇与环丙沙星随机对照治疗121例泌尿道细菌性感染临床评价

目的 :评价磷霉素氨丁三醇与环丙沙星随机对照治疗泌尿道细菌性感染的疗效和安全性。方法 :以环丙沙星为对照 ,采用随机化开放试验方法 ,观察试验药磷霉素氨丁三醇组 6 1例 ,对照药环丙沙星组 6 0例。结果 :磷霉素氨丁三醇与环丙沙星治疗泌尿系统感染的临床痊愈率分别为 85 .2 %和 83.3% ,有效率分别为 95 .1%和 95 .0 % ,细菌清除率分别为 92 .3%和92 .2 %。经统计学检验 ,上述两组结果差异无显著性 (P >0 .0 5 )。从分离到的 10 3株致病菌药敏试验结果分析发现 ,93株(90 .3% )致病菌对磷霉素氨丁三醇敏感 ,81株 (78.6 % )致病菌对环丙沙星敏感 ,经统计学处理两组的差异有显著性 (P =0 .0 2 1)。两药不良反应发生率分别为 4 .8%与 7.7%。结论 :磷霉素氨丁三醇对多数革兰阳性菌、阴性菌引起的泌尿道感染的治疗是安全有效的

A randomized controlled clinical trial of fosfomycin trometamol vs ciprofloxacin in the treatment of urinary tract infection

Objective: To evaluate the efficacy and safety of fosfomycin trometamol in the treatment of urinary tract infections. Methods: A randomized controlled clinical trial was conducted comparing the efficacy and safety of fosfomycin trometamol with ciprofloxacin in the treatment of 121 patients with urinary tract infections. The dosage of fosfomycin trometamol and ciprofloxacin was 3?000mg, once daily and 250?mg, twice daily respectively. The duration of treatment was five days in both groups. Results: The clinical efficacy rate, cure rate and bacterial eradication rate of fosfomycin trometamol were 85.2%, 95.1% and 92.3%; and those of ciprofloxacin were 83.3%, 95.0% and 92.2%, respectively. The adverse reactions rates of both drugs were 4.8 % and 7.7%, respectively. There were no statistical differences between the two groups. The susceptible rates of 103 clinical isolates to fosfomycin trometamol was 90.3%, which was much higher than that of ciprofloxacin (78.6%). Conclusion: Fosfomycin trometamol is effective and safe in treating urinary tract infections.